David Hale

Biography

DAVID HALE has been a board member of Cassiopea since 2015. He is also Chairman and CEO of Hale BioPharma Ventures, Chairman of Biocept Inc (NASDAQ) a cancer diagnostic company and Conatus Pharmaceuticals Inc, (NASDAQ) a liver disease company. He was Chairman of Santarus prior to its sale to Salix Pharmaceuticals in 2014, Chairman of SkinMedica prior to its sale to Allergan in 2012, Chairman of Microment prior to its sale to Amgen in 2012, Chairman of Somaxon Pharmaceuticals prior to its sale to Pernisx in 2013 and Crisi Medical Systems prior to its sale to Becton-Dickinson in 2015. He co-founded CancerVax in 2000 and served as its President and CEO until its merger with Micorment in 2006. From 1997 to 2000 he was President and CEO of Women First HealthCare. From 1987 to 1995 he was co-founder and Chairman of Viagene when the company was acquired by Chiron and from 1987 to 1997 he was Chairman, President and CEO of Gensia which merged with Sicor to become Gensia Sicor and then was acquired by Teva Pharmaceuticals. From 1982 to 1987 he was first COO, then President and then CEO of Hybritech when it was acquired by Eli Lilly. From 1980 to 1982 he was VP and General Manager of BBL Microbiology Systems, a division of Becton Dickinson and from 1971 to 1980 he held various marketing and sales management positions with Ortho Pharmaceutical Corporation and J&J Derm, both divisions of Johnson and Johnson.  

Research Interest

Marketing and sales management